6ª Edição

CHRONOS-3 study shows that the combination of copanlisib and rituximab increases progression-free survival in patients with indolent non-Hodgkin lymphoma

per: Grupo Oncoclínicas
CHRONOS-3 study shows that the combination of copanlisib and rituximab increases progression-free survival in patients with indolent non-Hodgkin lymphoma

Scientific commission

Carla Boquimpani
Carla Boquimpani
Evandro Fagundes
Evandro Fagundes
Jacques Tabacof
Jacques Tabacof
Rosa Arcuri Vasconcelos
Rosa Arcuri Vasconcelos

Contributors

Mariana Pivaro
Mariana Pivaro
Virgilio Farnese
Virgilio Farnese

The results of the CHRONOS-3 study opened the possibility for a new treatment regimen for patients with relapsed indolent non-Hodgkin’s lymphoma. The phase III clinical trial showed that the combination of copanlisib with the monoclonal antibody rituximab outperformed the combination of placebo and rituximab.

Virgilio Farnese, hematologist at the Triângulo Oncological Center (COT) in Uberlândia, a clinic of the Oncoclínicas Group in Minas Gerais, states that indolent non-Hodgkin lymphomas are a very heterogeneous group. For this reason, treatment varies widely, and may be based on chemotherapy regimens similar to those for aggressive lymphomas, with immunochemotherapy containing anthracycline and anti-CD20 monoclonal antibody, or just rituximab in monotherapy, or even radiotherapy alone.

In the present study, patients who received copanlisib plus rituximab had a progression-free survival of 21.5 months, versus 13.8 months in the placebo plus rituximab group. For hematologist Mariana Pivaro, from Centro Paulista de Oncologia (CPO), a clinic of Grupo Oncoclínicas in São Paulo, this is a relevant result, considering that these patients are treated multiple times and that the observed toxicity was acceptable. “In countries where the drug is already released in monotherapy, this study comes to modify clinical practice”, says the doctor. “We have a new perspective on chemotherapy-free treatment with low toxicity and increased progression-free survival.”

Read the full article with all the details of this study.

Access the full article of this study
Download
Share
Or share the link
Link copied to your desktop.L